Prospective, Multicenter Trial to Investigate the Safety and Efficacy of Percutaneous Tibial Nerve Stimulation for the Treatment of Fecal Incontinence

This study is currently recruiting participants.
Verified January 2013 by Uroplasty, Inc
Sponsor:
Information provided by (Responsible Party):
Uroplasty, Inc
ClinicalTrials.gov Identifier:
NCT01666405
First received: August 10, 2012
Last updated: January 4, 2013
Last verified: January 2013
  Purpose

The purpose of this study is to determine the effectiveness of percutaneous tibial nerve stimulation (PTNS) therapy with the Urgent® PC Neuromodulation System (Uroplasty, Inc., Minnetonka, MN, USA) for the treatment of fecal incontinence (FI).


Condition Intervention Phase
Fecal Incontinence
Device: Urgent(R) PC Neuromodulation System
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Prospective, Multicenter Trial to Investigate the Safety and Efficacy of Percutaneous Tibial Nerve Stimulation for the Treatment of Fecal Incontinence

Resource links provided by NLM:


Further study details as provided by Uroplasty, Inc:

Primary Outcome Measures:
  • Effectiveness [ Time Frame: 18 weeks ] [ Designated as safety issue: No ]
    To assess the effectiveness of PTNS by measuring the proportion of patients with ≥50% decrease in the number of fecal incontinence episodes per week based on the results of the 14-day bowel diary at 18 weeks compared to baseline

  • Safety [ Time Frame: 18 weeks ] [ Designated as safety issue: Yes ]
    To characterize adverse events experienced throughout the study


Estimated Enrollment: 30
Study Start Date: August 2012
Estimated Study Completion Date: August 2016
Estimated Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Urgent(R) PC Neuromodulation System
Urgent(R) PC Neuromodulation System
Device: Urgent(R) PC Neuromodulation System
The Urgent PC Neuromodulation System (Uroplasty, Inc., Minnetonka, MN, USA), device, is an easily administered neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve. This method of treatment is referred to as percutaneous tibial nerve stimulation (PTNS).

Detailed Description:

Pilot Study

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient history of chronic FI of more than staining for at least 6 months; staining defined as less than the size of a 25¢ piece (quarter)
  • Patient reported and/or failed ≥ 2 conservative therapies (e.g., diet/fiber modification, anti-diarrheal medication, pelvic floor muscle training, biofeedback, medical management, etc.)

Exclusion Criteria:

  • Pregnancy or intention to become pregnant during the course of the study
  • Implanted electro-medical device (i.e., pacemaker, defibrillator, deep brain stimulator, etc.)
  • Clinically significant neurological diseases or nerve damage impacting tibial nerve or pelvic floor function
  • Prone to excessive bleeding or bleeding diathesis
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01666405

Contacts
Contact: Megan O'Toole 952-426-6153 megan.otoole@uroplasty.com
Contact: Katie Welliver 952-426-6182 katie.welliver@uroplasty.com

Locations
United States, Minnesota
Minnesota Colon and Rectal Surgery Associates, Ltd. Recruiting
Minneapolis, Minnesota, United States, 55407
Contact: Jan Mullins, RN     651-225-7815        
United States, Washington
Providence Health and Services Recruiting
Spokane, Washington, United States, 99204
Contact: Joan Milton     509-474-4323     joan.e.milton@providence.org    
Principal Investigator: Shane McNevin, MD            
Sponsors and Collaborators
Uroplasty, Inc
  More Information

No publications provided

Responsible Party: Uroplasty, Inc
ClinicalTrials.gov Identifier: NCT01666405     History of Changes
Other Study ID Numbers: UPC032012
Study First Received: August 10, 2012
Last Updated: January 4, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by Uroplasty, Inc:
Fecal Incontinence
Bowel Incontinence

Additional relevant MeSH terms:
Fecal Incontinence
Rectal Diseases
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases

ClinicalTrials.gov processed this record on May 23, 2013